| human | Q5 |
| P496 | ORCID iD | 0000-0002-6524-612X |
| P27 | country of citizenship | Norway | Q20 |
| P108 | employer | Oslo University Hospital | Q3111191 |
| P734 | family name | Skotland | Q122838673 |
| Skotland | Q122838673 | ||
| Skotland | Q122838673 | ||
| P735 | given name | Tore | Q1548096 |
| Tore | Q1548096 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q39560067 | Addition of lysophospholipids with large head groups to cells inhibits Shiga toxin binding |
| Q90165876 | An emerging focus on lipids in extracellular vesicles |
| Q92451469 | Biological response and cytotoxicity induced by lipid nanocapsules |
| Q90357008 | Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft |
| Q39114334 | Cell density-induced changes in lipid composition and intracellular trafficking |
| Q26800100 | Cell-penetrating peptides: possibilities and challenges for drug delivery in vitro and in vivo |
| Q39201102 | Cellular effects of fluorodeoxyglucose: Global changes in the lipidome and alteration in intracellular transport |
| Q46269345 | Ceramide-containing liposomes with doxorubicin: time and cell-dependent effect of C6 and C12 ceramide |
| Q63547235 | Cholesterol Modulated Interdigitation of Long-Chain Sphingomyelin and Glycolipids |
| Q88723475 | Clathrin-independent endocytosis: an increasing degree of complexity |
| Q37861925 | Clathrin-independent endocytosis: mechanisms and function |
| Q82173067 | Comment on "short ligands affect modes of QD uptake and elimination in human cells" |
| Q47122638 | Cytotoxicity of Poly(Alkyl Cyanoacrylate) Nanoparticles |
| Q31137885 | Data including GROMACS input files for atomistic molecular dynamics simulations of mixed, asymmetric bilayers including molecular topologies, equilibrated structures, and force field for lipids compatible with OPLS-AA parameters |
| Q38760662 | Determining the Turnover of Glycosphingolipid Species by Stable-Isotope Tracer Lipidomics |
| Q85281514 | Development of nanoparticles for clinical use |
| Q95648598 | Diacylglycerol kinase and phospholipase D inhibitors alter the cellular lipidome and endosomal sorting towards the Golgi apparatus |
| Q43196106 | Different roles of the C-terminal end of Stx1A and Stx2A for AB5 complex integrity and retrograde transport of Stx in HeLa cells |
| Q89858196 | Drug-Loaded Photosensitizer-Chitosan Nanoparticles for Combinatorial Chemo- and Photodynamic-Therapy of Cancer |
| Q37642112 | Endocytosis and retrograde transport of Shiga toxin. |
| Q48050312 | Exogenous lysophospholipids with large head groups perturb clathrin-mediated endocytosis |
| Q90746523 | Exosomal lipid composition and the role of ether lipids and phosphoinositides in exosome biology |
| Q51467458 | Exosomal proteins as prostate cancer biomarkers in urine: From mass spectrometry discovery to immunoassay-based validation. |
| Q39849586 | Glycosphingolipid requirements for endosome-to-Golgi transport of Shiga toxin. |
| Q38286457 | Identification of prostate cancer biomarkers in urinary exosomes |
| Q38812803 | Interdigitation of long-chain sphingomyelin induces coupling of membrane leaflets in a cholesterol dependent manner |
| Q38181787 | Lipid requirements for entry of protein toxins into cells |
| Q38739765 | Lipids in exosomes: Current knowledge and the way forward |
| Q46450858 | Molecular lipid species in urinary exosomes as potential prostate cancer biomarkers |
| Q39094398 | Molecular lipidomics of exosomes released by PC-3 prostate cancer cells |
| Q37767060 | New metal-based nanoparticles for intravenous use: requirements for clinical success with focus on medical imaging |
| Q38845629 | Novel actions of 2-deoxy-D-glucose: protection against Shiga toxins and changes in cellular lipids |
| Q93184845 | Paclitaxel-loaded biodegradable ROS-sensitive nanoparticles for cancer therapy |
| Q99707944 | Physicochemical Characterization, Toxicity and In Vivo Biodistribution Studies of a Discoidal, Lipid-Based Drug Delivery Vehicle: Lipodisq Nanoparticles Containing Doxorubicin |
| Q39122055 | Protection against Shiga Toxins |
| Q37729388 | Protein toxins from plants and bacteria: probes for intracellular transport and tools in medicine |
| Q39017698 | Regulation of exosome release by glycosphingolipids and flotillins |
| Q38114338 | Retrograde transport of protein toxins through the Golgi apparatus |
| Q37831422 | Shiga toxin and its use in targeted cancer therapy and imaging |
| Q34298388 | Shiga toxins |
| Q38626585 | Size and concentration analyses of extracellular vesicles by nanoparticle tracking analysis: a variation study |
| Q91553178 | Small variations in nanoparticle structure dictate differential cellular stress responses and mode of cell death |
| Q99707945 | Structural Variants of poly(alkylcyanoacrylate) Nanoparticles Differentially Affect LC3 and Autophagic Cargo Degradation |
| Q39148164 | The anti-tumor drug 2-hydroxyoleic acid (Minerval) stimulates signaling and retrograde transport |
| Q35010145 | The ether lipid precursor hexadecylglycerol causes major changes in the lipidome of HEp-2 cells |
| Q39003334 | The ether lipid precursor hexadecylglycerol protects against Shiga toxins |
| Q35080308 | The ether lipid precursor hexadecylglycerol stimulates the release and changes the composition of exosomes derived from PC-3 cells |
| Q92105151 | The role of lipid species in membranes and cancer-related changes |
Search more.